metaPreg - Carvedilol (versus unexposed) during pregnancy

Carvedilol (versus unexposed) updated on 12-17-2024

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
2 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	2.36 [0.83, 6.69]	0%	2 studies	23	45	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	9.34 [3.23, 26.99]	0%	2 studies	226	45	not evaluable	ROB	18.16 [5.91; .]
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study